Literature DB >> 8913716

Origin and migration of an Afrikaner founder mutation FHAfrikaner-2 (V408M) causing familial hypercholesterolemia.

J C Defesche1, D E Van Diermen, M R Hayden, J P Kastelein.   

Abstract

Of the three major Afrikaner founder mutations, responsible for more than 95% of Familial Hypercholesterolemia cases among South African Afrikaners, one mutation called V408M or FHAfrikaner-2 was identified in the Netherlands. Subsequent analysis of a group of Canadian patients of Dutch origin with Familial Hypercholesterolemia revealed the presence of this mutation in western Canada. The founder of the Canadian family, suffering from Familial Hypercholesterolemia caused by V408M, was traced back to Andijk, a small village in the northwestern part of the Netherlands, a region from where the first settlers to South Africa departed in the 17th and 18th century. Further genealogical investigation demonstrated that the mutation must have been introduced in the Netherlands by an individual from northern Germany. Haplotype analysis resulted in the identification of the common haplotypes TaqI-, StuI+, AvaII+, NcoI+ in Canadian as well as Dutch patients with V408M. The results of this study further support the hypothesis that Dutch settlers introduced this Afrikaner founder mutation in the Afrikaner population in South Africa. After a recombinational event in the mutated gene, the mutation was also introduced in western Canada.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8913716

Source DB:  PubMed          Journal:  Gene Geogr        ISSN: 0394-249X


  2 in total

1.  Recurrent and founder mutations in inherited cardiac diseases in the Netherlands.

Authors:  J P van Tintelen; A A M Wilde; J D H Jongbloed
Journal:  Neth Heart J       Date:  2009-11       Impact factor: 2.380

2.  Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes.

Authors:  D M Kusters; R Huijgen; J C Defesche; M N Vissers; I Kindt; B A Hutten; J J P Kastelein
Journal:  Neth Heart J       Date:  2011-01-27       Impact factor: 2.380

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.